Strachan Judith A, Mowat Craig
Department of Blood Sciences, Ninewells Hospital and Medical School, NHS Tayside, Dundee, Scotland, UK.
Department of Gastroenterology, Ninewells Hospital and Medical School, Dundee, Scotland, UK.
EJIFCC. 2021 Feb 28;32(1):52-60. eCollection 2021 Feb.
Patients presenting to general practitioners (GPs) with new bowel symptoms can be difficult to assess since symptoms are poor predictors of pathology. National Institute for Health and Care Excellence referral guidelines highlight features that may suggest colorectal cancer (CRC) including rectal bleeding, palpable mass, iron deficiency anaemia, but also non-specific symptoms such as weight loss. In those patients referred for investigation on the basis of symptoms alone the yield of CRC is low (2-3%). Faecal immunochemical tests (FIT) quantify faecal haemoglobin (f-Hb) and are widely used in bowel screening programmes. A number of groups have now studied the utility of FIT in patients attending primary care with new bowel symptoms. Studies have concluded that if the FIT is negative and clinical assessment and full blood count normal then the risk of underlying significant bowel disease (SBD) is extremely small. Furthermore, patients with f-Hb ≥400 μgHb/g faeces have >50% risk of SBD and should be investigated urgently. Thus, a single f-Hb requested by GPs provides both a reliable prediction of the absence of SBD, and an objective assessment of the need and urgency of further investigation.
对于出现新的肠道症状的全科医生(GP)就诊患者,由于症状对病理情况的预测性较差,因此难以评估。英国国家卫生与临床优化研究所的转诊指南强调了可能提示结直肠癌(CRC)的特征,包括直肠出血、可触及肿块、缺铁性贫血,还有体重减轻等非特异性症状。在那些仅基于症状被转诊进行检查的患者中,结直肠癌的检出率较低(2%-3%)。粪便免疫化学检测(FIT)可定量粪便血红蛋白(f-Hb),并广泛应用于肠道筛查项目。现在有多个研究小组探讨了FIT在因新的肠道症状就诊于初级保健机构的患者中的应用价值。研究得出结论,如果FIT结果为阴性且临床评估和全血细胞计数正常,那么潜在严重肠道疾病(SBD)的风险极小。此外,粪便血红蛋白≥400μgHb/g粪便的患者患SBD的风险超过50%,应立即进行检查。因此,全科医生要求进行的单次粪便血红蛋白检测既能可靠地预测无SBD,又能客观评估进一步检查的必要性和紧迫性。